A
t the origin of cancer, there are changes in the structure of genes and abnormalities of the expression of these genes into proteins. Today, advances in genetics can detect some of these anomalies.Capable of detecting the expression of some twenty genes, the Oncotype DX test developed by the company Genomic Health would extrapolate accurately the risk of recurrence of breast cancer.
A U.S. team has tested the validity of this outil6, 7sur 675 samples of breast tumours in women treated with tamoxifen during 1980.
Obtained after genetic analysis, the score of recidivism has helped spread the women into three groups: low risk (51% of patients), intermediate (22%) or high (27%) of recurrences. Estimates of recidivism rates were at 10 years respectively for each group of 6.8%, 14.3% and 30.5%.
After statistical analysis, it became apparent that the predictive power of this test is independent of the patient's age and size of the tumor, the two criteria currently used in medical practice in addition to the severity of the tumor .
Related Post :
- Breast Cancer : Chemotherapy, A Test To Better Target Patients
- Breast Cancer: Revolution In Breast Reconstruction
- Breast Cancer : How To Deal With Larger Tumors ?
- Breast Cancer Development In France
- Breast Cancer : Yes To Conservative Surgery
- Breast Cancer : The Herceptin, A Targeted Treatment For Some Cancers Aggressive
- Breast Cancer Hormone Therapy
